Melinda Leigh Maconi

Melinda Leigh Maconi

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

9 July 2025 in Cancers
Verified
Journal Article
Open access
PDF file
MGMelany Anabel Garcia
Melany Anabel Garcia
CGCarley Geiss
Carley Geiss
RBRebecca M. Blackwell
Rebecca M. Blackwell
MMMelinda Leigh Maconi
Melinda Leigh Maconi
RARossybelle P Amorrortu
Rossybelle P Amorrortu
SVSusan Vadaparampil
Susan Vadaparampil
Background/objectives: Racial and ethnic minority patients are underrepresented in cancer clinical trials (CCTs) and multilevel strategies are required to increase participation. This study describes barriers and facilitators to minority CCT participation alongside feedback on a multilevel intervention (MLI) designed to reduce participation barriers, as posited by the socioecological model (SEM). Methods: Interviews with Moffitt Cancer Center (MCC) physicians, community physicians, patients with cancer, community residents, and clinical research coordinators (CRCs) were conducted from June 2023–February 2024. Verbal responses were analyzed using thematic analysis and categorized into SEM levels. Mean helpfulness scores rating interventions (from 1 (not helpful) to 5 (very helpful)) were summarized. Results: Approximately 50 interviews were completed. Thematic findings confirmed CCT referral and enrollment barriers across all SEM levels. At the community level, MCC patients and community residents felt that community health educators can improve patient experiences and suggested they connect patients to social/financial resources, assist with patient registration, and provide CCT education. While physicians and CRCs reacted positively to all institutional-level tools, the highest scored tool simultaneously addressed CCT referral and enrollment at the institution (e.g., trial identification/referrals) and interpersonal level (communication platform for community and MCC physicians) (mean = 4.27). At the intrapersonal level, patients were enthusiastic about a digital CCT decision aid (mean = 4.53) and suggested its integration into MCC’s patient portal. Conclusions: Results underscore the value of conducting formative research to tailor interventions to target population needs. Our approach can be leveraged by future researchers seeking to evaluate MLIs addressing additional CCT challenges or broader health topics.

17 January 2025 in JMIR Cancer
Verified
Journal Article
Open access
JRJessica N Rivera Rivera
Jessica N Rivera Rivera
MSMoran Snir
Moran Snir
ESEmilie Simmons
Emilie Simmons
TSTara Schmidlen
Tara Schmidlen
MSMisha Sholeh
Misha Sholeh
SVSusan Vadaparampil
Susan Vadaparampil
Background: National guidelines recommend germline genetic testing (GT) for all patients with early-onset colorectal cancer. With recent advances in targeted therapies and GT, these guidelines are expected to expand to include broader groups of patients with colorectal cancer. However, there is a shortage of genetic professionals to provide the necessary education and support for informed consent. As such, there is a pressing need to identify alternative approaches to facilitate and expedite access to GT. Objective: This study describes the development of a pretest education intervention, Nest-CRC, to facilitate the uptake of germline GT among patients with early-onset colorectal cancer. Patients with early-onset colorectal cancer and health care providers reviewed Nest-CRC, and their reactions and recommendations were captured using a nested mixed methods approach. Methods: Using the learner verification approach, we conducted 2 sequential phases of surveys and interviews with English- and Spanish-speaking patients with early-onset colorectal cancer and health care providers. The surveys assessed participants’ experiences with genetic services and provided immediate feedback on the Nest-CRC genetic education modules. Semistructured interviews evaluated participants’ perceptions of self-efficacy, attraction, comprehension, cultural acceptability, and usability of Nest-CRC. Survey data were analyzed using descriptive statistics (mean, median, and proportions), while interview data were analyzed through line-by-line coding of the transcribed interviews. After each phase, Nest-CRC was refined based on participants’ recommendations. Results: A total of 52 participants, including 39 patients with early-onset colorectal cancer and 13 providers, participated in the study. Of these, 19 patients and 6 providers participated in phase 1 (N=25), and 20 patients and 7 providers participated in phase 2 (N=27). Most participants (phase 1: 23/25, 92%, to 25/25, 100%; phase 2: 24/27, 89%, to 27/27, 100%) agreed that each of the 5 education modules was easy to understand and helpful; 13 patients reported no history of GT, with 11 (85%) expressing interest in GT and 2 (15%) remaining unsure after completing Nest-CRC. Participants reported that Nest-CRC provided sufficient information to help them decide about GT. The tool was deemed acceptable by individuals from diverse backgrounds, and participants found it visually attractive, easy to comprehend, and user-friendly. Conclusions: The findings revealed that Nest-CRC is a promising strategy for facilitating pretest education and promoting GT. Nest-CRC has been refined based on participant recommendations and will be re-evaluated.

13 November 2024 in Cancers
Verified
Journal Article
Open access
PDF file
Danielle TometichDanielle Tometich
Danielle Tometich
CHChristina Lee Hersh
Christina Lee Hersh
MMMelinda Leigh Maconi
Melinda Leigh Maconi
HFHayden J. Fulton
Hayden J. Fulton
DTDinorah Martinez Tyson
Dinorah Martinez Tyson
HJHeather S. L. Jim
Heather S. L. Jim
Background/Objectives: Cancer-related cognitive impairment (CRCI) is common and distressing for young adult (YA) cancer survivors; however, subjective CRCI is often attributed to psychological distress rather than true cognitive change. Thus, we aimed to generate hypotheses regarding potential common biobehavioral mechanisms of CRCI and psychological distress. Methods: We conducted semi-structured interviews with YA cancer survivors in peak years for frontal neurocognitive development (ages 18–30), and we asked them to describe their experiences with cognitive and mental health changes during and after treatment for their cancer. An applied thematic analysis was used to identify themes. Results: The participants were 20 YA cancer survivors who were, on average, 23 years old at diagnosis and 26 years old when interviewed. Five themes emerged regarding the connection between cognitive and mental health: depressed mood after diagnosis that decreased mental engagement, cancer-related anxiety consumed cognitive resources during treatment, a bidirectional “downward spiral” during treatment, frustration with forgetfulness, and self-criticism about long-term cognitive limitations. Additionally, participants described receiving minimal information about evidence-based strategies for managing CRCI. Conclusions: Future research is needed to examine common neurological mechanisms among symptoms of depression, anxiety, and CRCI and to address gaps in survivorship care for YA survivors with CRCI. Cognitive–behavioral interventions may address both cognitive and mental health.

12 April 2024 in JMIR Preprints
Verified
Preprint
Open access
JRJessica N Rivera Rivera
Jessica N Rivera Rivera
MSMoran Snir
Moran Snir
ESEmilie Simmons
Emilie Simmons
TSTara Schmidlen
Tara Schmidlen
MSMisha Sholeh
Misha Sholeh
SVSusan Vadaparampil
Susan Vadaparampil
BACKGROUND National guidelines recommend germline genetic testing (GT) for all patients with early-onset colorectal cancer. With recent advances in targeted therapies and GT, these guidelines are expected to expand to include broader groups of patients with colorectal cancer. However, there is a shortage of genetic professionals to provide the necessary education and support for informed consent. As such, there is a pressing need to identify alternative approaches to facilitate and expedite access to GT. OBJECTIVE This study describes the development of a pretest education intervention, Nest-CRC, to facilitate the uptake of germline GT among patients with early-onset colorectal cancer. Patients with early-onset colorectal cancer and health care providers reviewed Nest-CRC, and their reactions and recommendations were captured using a nested mixed methods approach. METHODS Using the learner verification approach, we conducted 2 sequential phases of surveys and interviews with English- and Spanish-speaking patients with early-onset colorectal cancer and health care providers. The surveys assessed participants’ experiences with genetic services and provided immediate feedback on the Nest-CRC genetic education modules. Semistructured interviews evaluated participants’ perceptions of self-efficacy, attraction, comprehension, cultural acceptability, and usability of Nest-CRC. Survey data were analyzed using descriptive statistics (mean, median, and proportions), while interview data were analyzed through line-by-line coding of the transcribed interviews. After each phase, Nest-CRC was refined based on participants’ recommendations. RESULTS A total of 52 participants, including 39 patients with early-onset colorectal cancer and 13 providers, participated in the study. Of these, 19 patients and 6 providers participated in phase 1 (N=25), and 20 patients and 7 providers participated in phase 2 (N=27). Most participants (phase 1: 23/25, 92%, to 25/25, 100%; phase 2: 24/27, 89%, to 27/27, 100%) agreed that each of the 5 education modules was easy to understand and helpful; 13 patients reported no history of GT, with 11 (85%) expressing interest in GT and 2 (15%) remaining unsure after completing Nest-CRC. Participants reported that Nest-CRC provided sufficient information to help them decide about GT. The tool was deemed acceptable by individuals from diverse backgrounds, and participants found it visually attractive, easy to comprehend, and user-friendly. CONCLUSIONS The findings revealed that Nest-CRC is a promising strategy for facilitating pretest education and promoting GT. Nest-CRC has been refined based on participant recommendations and will be re-evaluated.

9 March 2026 in Mindfulness
Verified
Journal Article
Open access
PDF file
MYMin-Jeong Yang
Min-Jeong Yang
SSSteven K. Sutton
Steven K. Sutton
CCCherell Cottrell-Daniels
Cherell Cottrell-Daniels
LRLee M. Ritterband
Lee M. Ritterband
RBRebecca M. Blackwell
Rebecca M. Blackwell
CVChristine Vinci
Christine Vinci
Objectives: Despite significant potential adverse health outcomes, many cancer survivors continue smoking. Few smoking cessation interventions have demonstrated efficacy above standard treatment for this population. Through a rigorous iterative process, we developed a prototype smartphone app that addresses both general and cancer-specific relapse risks in real time, incorporating cancer survivors’ feedback. We report findings from two studies: (1) Qualitative interviews and brief surveys to inform intervention development and (2) Usability testing of the prototype app in a 4-week single-arm pilot trial. Method: Cancer survivors (Study 1: n = 20; Study 2: n = 12) who had smoked at least one cigarette within the past 30 days were enrolled. Study 1 participants completed a 50-minutes Zoom interview and survey to inform intervention content and the app design. Subsequently, a prototype app was developed and tested for usability in Study 2, which included ecological momentary interventions (EMIs), three telehealth counseling sessions, and nicotine patches. Baseline and end-of-treatment (EOT) surveys and interviews were completed. Results: Key findings in Study 1 included high perceived helpfulness of mindfulness and EMIs for managing cravings and cancer-related stress, and a reported strong willingness to use the app. In Study 2, eleven participants used the app and completed counseling sessions. Participants reported high treatment acceptability, app usability, and ease of use. A key suggested improvement was adjusting the timing of app notifications. Conclusions: Results support continued investigation of this app. Next steps include testing the feasibility and acceptability of the app for smoking cessation. Preregistration: Study 2 is registered in ClinicalTrials.gov (NCT06476548).